SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

ZIM Laboratories informs about press release

21 Jul 2025 Evaluate
ZIM Laboratories has informed that it enclosed the Press Release relating to grant of Marketing Authorization for ‘Rizatriptan Benzoate Orally Disintegrating Strips’ in Australia by the Therapeutic Goods Administration (TGA), to ZIMTAS PTY LTD. (‘ZIMTAS’), Subsidiary of the company.

The above information is a part of company’s filings submitted to BSE. 

Zim Laboratories Share Price

76.08 3.39 (4.66%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×